WASHINGTON — Progressive lawmakers are increasingly warning that they would forcefully oppose any effort to set up a system of arbitration to help lower drug prices, a model that would fall short of their demands to allow the federal government to negotiate with drug companies.

It’s an idea that has the implicit backing of House Speaker Nancy Pelosi (D-Calif.), whose top health policy aide has been focused on the proposal in talks with other experts. The speaker’s backing of any eventual legislation could put it on the fast track for congressional action, though no bill on the issue has yet been introduced in Congress.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy